In Re Nektar Therapeutics Ninth Circuit Affirms Dismissal Of Securities Class Action Arising From Failure Clinical Drug Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana
On May 19, 2022, a panel of the Ninth Circuit unanimously affirmed the district court's dismissal of a putative securities fraud class action accusing Nektar Therapeutics and several of.